Claims for Patent: 7,981,605

Summary for Patent: 7,981,605

Title:	Epidermal growth factor receptor mutations
Abstract:	Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3\'-kinase (\"Pl3K\"), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant Pl3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described.
Inventor(s):	Freeman; Daniel J. (Thousand Oaks, CA), Juan; Todd (Newbury Park, CA), Radinsky; Robert (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	11/361,711
Patent Claims:	1. A method of determining resistance to gefitinib treatment but not panitumumab treatment in a subject suffering from non-small cell lung cancer comprising determining the presence or absence of EGFr mutation T790M in the cancer, wherein the presence of EGFr mutation T790M indicates that the cancer will be resistant to gefitinib treatment but not panitumumab treatment. 2. A method for determining resistance to gefitinib treatment in a patient with non-small cell lung cancer, comprising determining the presence of the EGFr mutation T790M in a sample from said patient, wherein the presence of the EGFr mutation T790M in one or more mutant EGFr polypeptides indicates resistance to treatment with gefitinib.

Details for Patent 7,981,605

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2025-02-24